WallStreetZenWallStreetZen

NASDAQ: IMMX
IMMIX Biopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IMMX

Based on 6 analysts offering 12 month price targets for IMMIX Biopharma Inc

Min Forecast
$19.00+62.39%
Avg Forecast
$23.50+100.85%
Max Forecast
$27.00+130.77%

Should I buy or sell IMMX stock?

Based on 6 analysts offering ratings for IMMIX Biopharma Inc.

Strong Buy
Strong Buy
2 analysts 33.33%
Buy
4 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IMMX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates IMMX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their IMMX stock forecasts and price targets.

IMMX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-15
lockedlocked$00.00+00.00%2026-08-11
lockedlocked$00.00+00.00%2026-08-10
lockedlocked$00.00+00.00%2026-07-22
lockedlocked$00.00+00.00%2026-06-18
Anonymous
LifeSci Capital
BuyInitiates Coverage On$19.00+62.39%2026-06-17
Citizens
Top 20%
81
BuyReiterates$23.00+96.58%2026-03-27

1 of 1

Forecast return on equity

Is IMMX forecast to generate an efficient return?

Company
16.42%
Industry
22.6%
Market
168.99%
IMMX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IMMX forecast to generate an efficient return on assets?

Company
15.72%
Industry
23.77%
IMMX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IMMX earnings per share forecast

What is IMMX's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$0.74
Avg 2 year Forecast
-$0.84
Avg 3 year Forecast
-$0.22

IMMX revenue forecast

What is IMMX's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$26.9M
Avg 3 year Forecast
$148.7M

IMMX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMMX$11.70$23.50+100.85%Strong Buy
AVTX$15.72$45.73+190.88%Strong Buy
ATTO$18.17$41.50+128.40%Strong Buy
OBX$13.41N/AN/ABuy
LXRX$1.86$3.10+66.67%Strong Buy
View Top Biotech Stocks

IMMIX Biopharma Stock Forecast FAQ

Is IMMIX Biopharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: IMMX) stock is to Strong Buy IMMX stock.

Out of 6 analysts, 2 (33.33%) are recommending IMMX as a Strong Buy, 4 (66.67%) are recommending IMMX as a Buy, 0 (0%) are recommending IMMX as a Hold, 0 (0%) are recommending IMMX as a Sell, and 0 (0%) are recommending IMMX as a Strong Sell.

If you're new to stock investing, here's how to buy IMMIX Biopharma stock.

What is IMMX's earnings growth forecast for 2026-2028?

(NASDAQ: IMMX) IMMIX Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.85%.

IMMIX Biopharma's earnings in 2026 is -$39,917,211.On average, 10 Wall Street analysts forecast IMMX's earnings for 2026 to be -$52,860,399, with the lowest IMMX earnings forecast at -$56,787,907, and the highest IMMX earnings forecast at -$40,562,791. On average, 10 Wall Street analysts forecast IMMX's earnings for 2027 to be -$60,193,179, with the lowest IMMX earnings forecast at -$101,657,365, and the highest IMMX earnings forecast at -$15,023,256.

In 2028, IMMX is forecast to generate -$15,688,572 in earnings, with the lowest earnings forecast at -$18,929,302 and the highest earnings forecast at -$12,018,605.

What is IMMX's revenue growth forecast for 2026-2028?

(NASDAQ: IMMX) IMMIX Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.91%.

IMMIX Biopharma's revenue in 2026 is $0.On average, 10 Wall Street analysts forecast IMMX's revenue for 2026 to be $0, with the lowest IMMX revenue forecast at $0, and the highest IMMX revenue forecast at $0. On average, 10 Wall Street analysts forecast IMMX's revenue for 2027 to be $1,926,768,344, with the lowest IMMX revenue forecast at $0, and the highest IMMX revenue forecast at $7,052,488,653.

In 2028, IMMX is forecast to generate $10,637,895,992 in revenue, with the lowest revenue forecast at $5,579,565,717 and the highest revenue forecast at $18,390,611,450.

What is IMMX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: IMMX) forecast ROA is 15.72%, which is lower than the forecast US Biotechnology industry average of 23.77%.

What is IMMX's Price Target?

According to 6 Wall Street analysts that have issued a 1 year IMMX price target, the average IMMX price target is $23.50, with the highest IMMX stock price forecast at $27.00 and the lowest IMMX stock price forecast at $19.00.

On average, Wall Street analysts predict that IMMIX Biopharma's share price could reach $23.50 by Sep 15, 2027. The average IMMIX Biopharma stock price prediction forecasts a potential upside of 100.85% from the current IMMX share price of $11.70.

What is IMMX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: IMMX) IMMIX Biopharma's current Earnings Per Share (EPS) is -$0.88. On average, analysts forecast that IMMX's EPS will be -$0.74 for 2026, with the lowest EPS forecast at -$0.79, and the highest EPS forecast at -$0.57. On average, analysts forecast that IMMX's EPS will be -$0.84 for 2027, with the lowest EPS forecast at -$1.42, and the highest EPS forecast at -$0.21. In 2028, IMMX's EPS is forecast to hit -$0.22 (min: -$0.26, max: -$0.17).

What is IMMX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: IMMX) forecast ROE is 16.42%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.